GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Betta Pharmaceuticals Co Ltd (SZSE:300558) » Definitions » PB Ratio

Betta Pharmaceuticals Co (SZSE:300558) PB Ratio : 3.11 (As of May. 15, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Betta Pharmaceuticals Co PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-15), Betta Pharmaceuticals Co's share price is ¥41.08. Betta Pharmaceuticals Co's Book Value per Share for the quarter that ended in Mar. 2024 was ¥13.20. Hence, Betta Pharmaceuticals Co's PB Ratio of today is 3.11.

The historical rank and industry rank for Betta Pharmaceuticals Co's PB Ratio or its related term are showing as below:

SZSE:300558' s PB Ratio Range Over the Past 10 Years
Min: 2.73   Med: 8.48   Max: 32.09
Current: 3.11

During the past 13 years, Betta Pharmaceuticals Co's highest PB Ratio was 32.09. The lowest was 2.73. And the median was 8.48.

SZSE:300558's PB Ratio is ranked worse than
68.72% of 956 companies
in the Drug Manufacturers industry
Industry Median: 2.01 vs SZSE:300558: 3.11

During the past 12 months, Betta Pharmaceuticals Co's average Book Value Per Share Growth Rate was 12.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 7.80% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 19.00% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 23.70% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Betta Pharmaceuticals Co was 51.00% per year. The lowest was -6.60% per year. And the median was 25.10% per year.

Back to Basics: PB Ratio


Betta Pharmaceuticals Co PB Ratio Historical Data

The historical data trend for Betta Pharmaceuticals Co's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Betta Pharmaceuticals Co PB Ratio Chart

Betta Pharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.71 10.71 7.27 4.24 4.11

Betta Pharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.01 3.97 4.57 4.11 3.10

Competitive Comparison of Betta Pharmaceuticals Co's PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Betta Pharmaceuticals Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Betta Pharmaceuticals Co's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Betta Pharmaceuticals Co's PB Ratio distribution charts can be found below:

* The bar in red indicates where Betta Pharmaceuticals Co's PB Ratio falls into.



Betta Pharmaceuticals Co PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Betta Pharmaceuticals Co's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=41.08/13.196
=3.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Betta Pharmaceuticals Co  (SZSE:300558) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Betta Pharmaceuticals Co PB Ratio Related Terms

Thank you for viewing the detailed overview of Betta Pharmaceuticals Co's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Betta Pharmaceuticals Co (SZSE:300558) Business Description

Traded in Other Exchanges
N/A
Address
No.355, Xingzhong Road, Yuhang Economic and Technological Development Zone, Zhejiang Province, Hangzhou, CHN
Betta Pharmaceuticals Co Ltd is a hi-tech pharmaceutical enterprise focuses on research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates through China.

Betta Pharmaceuticals Co (SZSE:300558) Headlines

No Headlines